When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...